Filing Flows › Comparisons › CDNA vs FLGT
CareDx vs Fulgent Genetics: CDNA and FLGT compared
CareDx is the larger company: $139M of revenue in its latest quarter (Q3 2026) against $90.4M for Fulgent Genetics (Q3 2026). CareDx is growing faster (+39% against +8% a year earlier). CareDx is more profitable, with an operating margin of 5.8% against -24.9%.
Where the money goes: CDNA and FLGT
CareDx (CDNA) · Q3 2026
CareDx, Q3 2026: revenue $139M (+39% year over year), operating margin 5.8%, net earnings $19.3M, operating cash flow $12.7M. The chart follows the revenue to costs, profit and cash.
Fulgent Genetics (FLGT) · Q3 2026
Fulgent Genetics, Q3 2026: revenue $90.4M (+8% year over year), operating margin -24.9%, net loss $13.3M, operating cash flow $109M. The chart follows the revenue to costs, profit and cash.
| CareDx (CDNA) | Fulgent Genetics (FLGT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $139M | $90.4M |
| Revenue growth, Y/Y | +39% | +8% |
| Operating margin | 5.8% | -24.9% |
| Net earnings | $19.3M | −$13.3M |
| Net margin | 13.8% | -14.8% |
| Operating cash flow | $12.7M | $109M |
| Free cash flow | $11.1M | $107M |
| Market value | $3.5B | — |
| P/E | 26.6× | — |
| Analysts’ mean target | $93.50 | — |
Where the revenue comes from
CareDx
- Testing services revenue: $119M (86%)
- Patient and digital solutions revenue: $20.2M (14%)
Questions
Which is bigger, CareDx or Fulgent Genetics?
CareDx is the larger company: $139M of revenue in its latest quarter (Q3 2026) against $90.4M for Fulgent Genetics (Q3 2026).
Is CareDx or Fulgent Genetics growing faster?
CareDx is growing faster (+39% against +8% a year earlier).
Which is more profitable, CareDx or Fulgent Genetics?
CareDx is more profitable, with an operating margin of 5.8% against -24.9%.
More: CareDx earnings · how CareDx makes money · Fulgent Genetics earnings · how Fulgent Genetics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.